Chem Pharm Bull (Tokyo). 2026;74(9):708-714. doi: 10.1248/cpb.c26-00322.
ABSTRACT
Excessive salt intake is a major risk factor for cardiovascular, cerebrovascular, and renal diseases, highlighting the need for strategies to reduce intestinal sodium absorption. Ammonium alginate (AAL) suppresses the postprandial increase in blood sodium levels and promotes fecal sodium excretion via ion-exchange and gel-mediated sodium entrapment in the gastrointestinal tract. However, its unpleasant odor and taste, along with its high viscosity upon contact with saliva, cause oral discomfort and limit its practical use in food and clinical settings. In this study, AAL granules were developed to improve their handling and sensory properties while preserving their sodium-sequestration functionality. Granulation with the AQshelax coating was performed using a fluidized-bed granulator, and the process parameters were optimized using a Box-Behnken experimental design. The optimized granules exhibited improved flowability and markedly reduced viscosity upon contact with saliva, resulting in enhanced sensory evaluation scores. In vitro sodium-binding assays demonstrated that the optimized granules retained a sodium-binding capacity comparable to that of unprocessed AAL powder. Furthermore, in salt-loaded mice, granulated AAL maintained its ability to suppress elevated blood sodium levels in vivo. These findings indicate that design-of-experiments-guided granulation successfully overcame key formulation limitations without compromising sodium-sequestration functionality, thereby enabling the practical dietary and clinical application of AAL as a sodium-excreting agent.
PMID:42749623 | DOI:10.1248/cpb.c26-00322